NEW YORK (GenomeWeb) – Danaher today initiated guidance for adjusted diluted EPS for Fiscal Year 2016 in the range of $4.80 to $4.95.
The firm assumed core revenue growth between 2 percent and 3 percent for FY 2016.
The company also reaffirmed adjusted diluted EPS for the fourth quarter of 2015 to be in the range of $1.25 to $1.29. The average Wall Street estimate is for EPS of $1.25 in Q4.
In a research note, Evercore ISI analyst Ross Muken said the guidance was "in-line with expectations," adding that demand continued to be strong for the life science and diagnostic sectors of Danaher's business. "The guidance is a solid outcome especially given the negative back-drop of 3M and Dover, who recently disappointed, and we expect a generally positive reaction from investors," he wrote.
In Wednesday morning trade on the New York Stock Exchange, shares of Danaher were up a fraction of 1 percent at $92.96.